0 104

Cited 0 times in

Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study

DC FieldValueLanguage
dc.contributor.author방승민-
dc.contributor.author조인래-
dc.contributor.author강화평-
dc.contributor.author조중현-
dc.contributor.author이희승-
dc.contributor.author정문재-
dc.contributor.author박정엽-
dc.contributor.author박승우-
dc.contributor.author송시영-
dc.contributor.author정재복-
dc.contributor.author안찬식-
dc.contributor.author박미숙-
dc.date.accessioned2018-11-15T16:40:20Z-
dc.date.available2018-11-15T16:40:20Z-
dc.date.issued2017-
dc.identifier.issn0093-7754-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/165167-
dc.description.abstractPancreatic cancer has poor prognosis because of its rapid progression and treatment resistance. Based on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT), a combination regimen of gemcitabine with nab-paclitaxel is currently used as standard therapy for the treatment of metastatic pancreatic cancer. However, because studies in Asian populations are lacking, we investigated the treatment efficacy and safety of this combination therapy in Korean population. Patients with metastatic pancreatic cancer (n=81) treated with gemcitabine and nab-paclitaxel (1,000 and 125 mg/m2, respectively) as the first-line chemotherapy from January 2016 were identified using the Severance Hospital Pancreatic Cancer Cohort Registry. Treatment efficacy and treatment-related adverse events (AEs) were analyzed. The median follow-up period was 10.7 months (range, 1.5-23.3 months). Median overall survival, progression-free survival, and objective response rates were 12.1 months (95% confidence interval [CI], 10.7-not estimable), 8.4 months (95% CI, 5.0-11.8), and 46.9%, respectively. The incidence of grade ≥3 neurotoxicity and neutropenia were 18.5% and 46.9%, respectively. Febrile neutropenia and grade ≥3 gastrointestinal AEs occurred in 13 (16.0%) and 16 (19.8%) patients, respectively. Dose reductions because of AEs were required in 60.5% of patients. The combination of gemcitabine with nab-paclitaxel is an effective anti-cancer regimen in Korean population of patients with metastatic pancreatic adenocarcinoma. However, careful monitoring and management are required because of occurrence of treatment-related AEs.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherW.B. Saunders-
dc.relation.isPartOfSeminars in Oncology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleEfficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorIn Rae Cho-
dc.contributor.googleauthorHuapyong Kang-
dc.contributor.googleauthorJung Hyun Jo-
dc.contributor.googleauthorHee Seung Lee-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorJeong Youp Park-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorJae Bock Chung-
dc.contributor.googleauthorChansik An-
dc.contributor.googleauthorMi-Suk Park-
dc.contributor.googleauthorSo Young Jung-
dc.contributor.googleauthorSeungmin Bang-
dc.identifier.doi10.1053/j.seminoncol.2018.01.001-
dc.contributor.localIdA01786-
dc.contributor.localIdA01786-
dc.contributor.localIdA03890-
dc.contributor.localIdA00100-
dc.contributor.localIdA03912-
dc.contributor.localIdA03349-
dc.contributor.localIdA03602-
dc.contributor.localIdA01647-
dc.contributor.localIdA01551-
dc.contributor.localIdA02035-
dc.contributor.localIdA03706-
dc.contributor.localIdA02268-
dc.contributor.localIdA01463-
dc.contributor.localIdA01786-
dc.relation.journalcodeJ02938-
dc.identifier.eissn1532-8708-
dc.identifier.pmid29935903-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0093775417301392-
dc.subject.keywordchemotherapy-
dc.subject.keywordgemcitabine-
dc.subject.keywordnab-paclitaxel-
dc.subject.keywordpancreatic cancer-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameBang, Seungmin-
dc.contributor.alternativeNameCho, In Rae-
dc.contributor.alternativeNameKang, Hwa Pyoung-
dc.contributor.alternativeNameJo, Jung Hyun-
dc.contributor.alternativeNameLee, Hee Seung-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.alternativeNameAn, Chan Sik-
dc.contributor.alternativeNamePark, Mi Sook-
dc.contributor.affiliatedAuthor방승민-
dc.contributor.affiliatedAuthor조인래-
dc.contributor.affiliatedAuthor강화평-
dc.contributor.affiliatedAuthor조중현-
dc.contributor.affiliatedAuthor이희승-
dc.contributor.affiliatedAuthor정문재-
dc.contributor.affiliatedAuthor박정엽-
dc.contributor.affiliatedAuthor박승우-
dc.contributor.affiliatedAuthor송시영-
dc.contributor.affiliatedAuthor정재복-
dc.contributor.affiliatedAuthor안찬식-
dc.contributor.affiliatedAuthor박미숙-
dc.citation.volume44-
dc.citation.number6-
dc.citation.startPage420-
dc.citation.endPage427-
dc.identifier.bibliographicCitationSeminars in Oncology, Vol.44(6) : 420-427, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.